Heron Therapeutics Inc (HRTX) Stock Analysis
Verdict: AVOID
A distressed biotech death spiral: high debt and earnings misses overshadow product margins, necessitating a 'Show Me' phase to avoid insolvency.
Investment score: 18/100
Analysis as of
Is Heron Therapeutics Inc stock worth reviewing? AI model thesis
HRTX is in a technical and fundamental freefall, trading at 52-week lows with negative equity in 2024 and heavy debt.
7-factor investment score
- Valuation: 30/100 (weight 20%)
- Financial Health: 15/100 (weight 15%)
- Technical Momentum: 5/100 (weight 15%)
- Earnings Quality: 10/100 (weight 15%)
- Insider Sentiment: 20/100 (weight 10%)
- Analyst Consensus: 40/100 (weight 10%)
- Risk-Adjusted Return: 10/100 (weight 15%)
Heron Therapeutics Inc opportunities and risks
What speaks for HRTX
- Path to Profitability 2028
What speaks against HRTX
- Severe Liquidity and Dilution Risk
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| HRTX | n/a | 0.4x | n/a | 71.1% | -20.5% | -34.6% |
| GANX | n/a | 0.0x | n/a | 0.0% | 0.0% | -25.4% |
| CLNN | n/a | 450.0x | n/a | -182.1% | -25009.7% | -30.0% |
| XBIT | n/a | 0.0x | 1.1x | 0.0% | 0.0% | -59.1% |
| SERA | n/a | 1246.2x | n/a | -191.2% | -56386.0% | -38.8% |
| ACET | n/a | 0.0x | n/a | 0.0% | 0.0% | -126.3% |
| Peer median | n/a | 0.0x | n/a | 0.0% | 0.0% | -38.8% |
Frequently asked questions about Heron Therapeutics Inc (HRTX)
Is HRTX stock a good investment?
The cached TradeMates AI model rates Heron Therapeutics Inc as AVOID with an investment score of 18/100. HRTX is in a technical and fundamental freefall, trading at 52-week lows with negative equity in 2024 and heavy debt. This is algorithmic model output, not personal investment advice.
Is HRTX stock a buy?
The TradeMates model verdict for HRTX is AVOID with an investment score of 18/100. Treat this as a model signal to review, not a personal buy recommendation.